From cytokine to myokine: The emerging role of interleukin-6 in metabolic regulation

Immunology and Cell Biology

Volumn 92, Issue 4, 2014, Pages 331-339

  Pal, Martin ^a   Febbraio, Mark A ^a   Whitham, Martin ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GLUCOSE; INSULIN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; MYOKINE; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; DIABETES MELLITUS; EXERCISE; GLUCOSE INTOLERANCE; HUMAN; IMMUNE SYSTEM; INFECTION; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC DISORDER; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN SECRETION; REVIEW; SEDENTARY LIFESTYLE; SKELETAL MUSCLE; ANIMAL; IMMUNITY; IMMUNOLOGY; METABOLISM; PATHOLOGY;

ANIMALS; EXERCISE; HUMANS; IMMUNITY; INSULIN RESISTANCE; INTERLEUKIN-6; METABOLISM; MUSCLE, SKELETAL; OBESITY;

EID: 84898963539     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2014.16     Document Type: Review

References (104)

1. Mathis D, Shoelson S. Immunometabolism: an emerging frontier. Nat Rev Immunol 2011; 11: 81.
2. Magliano DJ, Shaw JE, Shortreed SM, Nusselder WJ, Liew D, Barr EL et al. Lifetime risk and projected population prevalence of diabetes. Diabetologia 2008; 51: 2179-2186.
3. Pedersen B, Febbraio M. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol 2012; 8: 457-465.
4. Pedersen B, Febbraio M. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev 2008; 88: 1379-1406.
5. Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986; 324: 73-76.
6. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994; 368: 339-342.
7. Cressman D, Greenbaum L, DeAngelis R, Ciliberto G, Furth E, Poli V et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996; 274: 1379-1383.
8. Gruber S, Straub B, Ackermann P, Wunderlich C, Mauer J, Seeger J et al. Obesity promotes liver carcinogenesis via Mcl-1 stabilization independent of IL-6RI± signaling. Cell Rep 2013; 4: 669-680.
9. Grivennikov S, Karin E, Terzic J, Mucida D, Yu G-Y, Vallabhapurapu S et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer . Cancer Cell 2009; 15: 103-113.
10. Naugler W, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 2008; 14: 109-119.
11. Boulanger M, Chow D-c, Brevnova E, Garcia K. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science 2003; 300: 2101-2104.
12. Heinrich P, Behrmann I, Haan S, Hermanns H, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003; 374 (Pt 1), 1-20.
13. Wunderlich C, Hövelmeyer N, Wunderlich F. Mechanisms of chronic JAK-STAT3-SOCS3 signaling in obesity. JAKSTAT 2013; 2: 2 e23878.
14. Nicola N, Greenhalgh C. The suppressors of cytokine signaling (SOCS) proteins: important feedback inhibitors of cytokine action. Exp Hematol 2000; 28: 1105-1112.
15. Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koishihara Y et al. Soluble forms of the int erleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 1993; 82: 1120-1126.
16. McFarland-Mancini M, Funk H, Paluch A, Zhou M, Giridhar P, Mercer C et al. Differences in wound healing in mice with deficiency of IL-6 versus IL-6 receptor. J Immunol 2010; 184: 7219-7228.
17. Wunderlich FT Ströhle P Könner AC Gruber S Tovar S Brönneke HS et al. Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action Cell Metab 2010 12 237-249.
18. Wunderlich FT, Ströhle P, Könner AC, Gruber S, Tovar S, Brönneke HS et al. Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action. Cell Metab 2010; 12: 237-249. 18 Jones S. Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol 2005; 175: 3463-3468.
19. Kaplanski G, Marin Vr, Montero-Julian Fl, Mant ovani A, Farnarier C. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol 2003; 24: 25-29.
20. Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997; 6: 315-325.
21. Chomarat P, Banchereau J, Davoust J, Palucka A. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 2000; 1: 510-514.
22. Jenkins B, Grail D, Inglese M, Quilici C, Bozinovski S, Wong P et al. Imbalanced gp130-dependent signaling in macrophages alters macrophage colony-stimulating factor responsiveness via regulation of c-fms expression. Mol Cell Biol 2004; 24: 1453-1463.
23. Rabe Br, Chalaris A, May U, Waetzig G, Seegert D, Williams A et al. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. B lood 2008; 111: 1021-1028.
24. Dienz O, Eaton S, Bond J, Neveu W, Moquin D, Noubade R et al. The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells. J Exp Med 2009; 206: 69-78.
25. Eddahri F, Denanglaire Sb, Bureau F, Spolski R, Leonard W, Leo O et al. Interleukin-6/STAT3 signaling regulates the ability of naive T cells to a cquire B-cell help capacities. Blood 2009; 113: 2426-2433.
26. Scheller Jr, Chalaris A, Schmidt-Arras D, Rose-John S. The pro-and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011; 1813: 878-888.
27. Diehl S, Rincón M. The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol 2002; 39: 531-536.
28. Sofi M, Li W, Kaplan M, Chang C-H. Elevated IL-6 expression in CD4 T cells via PKCtheta and NF-kappaB induces Th2 cytokine production. Mol Immunol 2009; 46: 1443-1450.
29. Manga n P, Harrington L, O'Quinn D, Helms W, Bullard D, Elson C et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006; 441: 231-234.
30. Qin H, Wa ng L, Feng T, Elson C, Niyongere S, Lee S et al. TGF-beta promotes Th17 cell development through inhibition of SOCS3. J Immunol 2009; 183: 97-105.
31. Bettelli E, Carrier Y, Gao W, Korn T, Strom T, Oukka M et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235-238.
32. Dominitzki S, Fanti ni M, Neufert C, Nikolaev A, Galle P, Scheller Jr et al. Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+ CD25 T cells. J Immunol 2007; 179: 2041-2045.
33. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
34. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesityinduced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389: 610-614.
35. Lazar MA . How obesity causes diabetes: not a tall tale. Science 2005; 307: 373-375.
36. Roytblat L, Rachinsky M, Fisher A, Greemberg L, Shapira Y, Douvdevani A et al. Raised interleukin-6 levels in obese patients. Obes Res 2000; 8: 673-675.
37. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-334.
38. Vozarova B, Weyer C, Hanson K, Tataranni P, Bogardus C, Pratley R. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretio n. Obes Res 2001; 9: 414-417.
39. Kern P Ranganathan S Li C Wood L Ranganathan G Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001 280 51.
40. Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M et al. Elevated levels of interleukin are re duced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000; 85: 3338-3342.
41. Carey AL, Bruce CR, Sacchetti M, Anderson MJ, Olsen DB, Saltin B et al. Interleukin-6 and tumor necrosis factor-alpha are not increased in patients with Type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness. Diabetologia 2004; 47: 1029-1037.
42. Weisberg S, McCann D, Desai M, Rosenbaum M, Leibel R, Ferrante A. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808.
43. Deng T, Lyon C, Minze L, Lin J, Zou J, Liu J et al. Class II major histocompatibility complex plays an essential role in obesity-induced adipose inflammation. Cell Metab 2013; 17: 411-42 2.
44. Feve B, Bastard J-P. The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 2009; 5: 305-311.
45. Murano I, Barbatelli G, Pari sani V, Latini C, Muzzonigro G, Castellucci M et al. Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice. J Lipid Res 2008; 49: 1562-1568.
46. Elgazar-Carmon V, Rudich A, Hadad N, Levy R. Neutrophils transiently infiltrate intraabdominal fat early in the course of high-fat feeding. J Lipid Res 2008; 49: 1894-1903.
47. Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med 2009; 15: 930-939.
48. DeFuria J, Belkina A, Jagannathan-Bogdan M, Snyder-Cappione J, Carr J, Nersesova Y et al. B cells promote inflammation in obesity and type 2 diabetes through regulation of T-cel l function and an inflammatory cytokine profile. Proc Natl Acad Sci USA 2013; 110: 5133-5138.
49. Nishimura S, Manabe I, Nagai R. Adipose tissue inflammation in obesity and metabolic syndrome. Disc Med 2009; 8: 55-60.
50. Priceman S, Kujawski M, Shen S, Cherryholmes G, Lee H, Zhang C et al. Regulation of adipose tissue T cell subsets by Stat3 is crucial for diet-induced obesity an d insulin resistance. Proc Natl Acad Sci USA 2013; 110: 13079-13084.
51. Winer D, Winer S, Shen L, Wadia P, Yantha J, Paltser G et al. B cells promote insulin resistance through modul ation of T cells and production of pathogenic IgG antibodies. Nat Med 2011; 17: 610-617.
52. van de Veerdonk F, Lauwerys B, Marijnissen R, Timmermans K, Di Padova F, Koenders M et al. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum 2011; 63: 1507-1516.
53. Lagathu C, Bastard J-P, Auclair M, Maachi M, Capeau J, Caron M. Chronic interleu kin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun 2003; 311: 372-379.
54. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 2003; 278: 45777-45784.
55. Senn J, Klover P, Nowak I, Mooney R. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002; 51: 3391-3399.
56. Klover P, Zimmers T, Koniaris L, Mooney R. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 2003; 52: 2784-2789.
57. Klover PJ, Clementi AH, Mooney RA. Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 2005; 146: 3417-3427.
58. Cai D, Yuan M, Frantz D, Melendez P, Hansen L, Lee J et al. Local and systemic insulin resistance resu lting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005; 11: 183-190.
59. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997; 387: 924-929.
60. Ueki K Kondo T Kahn C Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms Mol Cell Biol 2004 24 5434-5446.
61. Senn J, Klover P, Nowak I, Zimmers T, Koniaris L, Furlanetto R et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 2003; 278: 13740-13746.
62. Holmes A, Mesa J, Neill B, Chung J, Carey A, Steinberg G et al. Prolonged interleukin-6 administration enhances glucose tolerance and increases skeletal muscle PPAR alpha and UCP2 expression in rats. J Endocrinol 2008; 198: 367-374.
63. Weigert C, Hennige A, Lehmann R, Brodbeck K, Baumgartner F, Schaüble M et al. Direct cross-talk of interleukin-6 and i nsulin signal transduction via insulin receptor substrate-1 in skeletal muscle cells. J Biol Chem 2006; 281: 7060-7067.
64. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002; 8: 75-79.
65. Di Gregorio GB, Hensley L, Lu T, Ranganathan G, Kern PA. Lipid and carbohydrate metabolis m in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity. Am J Physiol Endocrinol Metab 2004; 287: E182-E187.
66. Matthews VB, Allen TL, Risis S, Chan MH, Henstridge DC, Watson N et al. Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia 2010; 53: 2431-2441.
67. Quintana A, Erta M, Ferrer B, Comes G, Giralt M, Hidalgo J. Astrocyte-specific deficiency of interleukin-6 and its receptor reveal specific roles in survival, body weight and behavior. Brain Behav Immun 2013; 27: 162-173.
68. Stanford K, Middelbeek R, Townsend K, An D, Nygaard E, Hitchcox K et al. Brown adipose tissue regulates glucose homeostasis and insulin sensitivity. J Clin Invest 2013; 123: 215-223.
69. Peters M, Schirmacher P, Goldschmitt J, Odenthal M, Peschel C, Fattori E et al. Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6-sIL-6R double transgenic mice. J Exp Med 1997; 185: 755-766.
70. Hidalgo J, Florit S, Giralt M, Ferrer B, Keller C, Pilegaard H. Transgenic mice with astrocyte-targeted production of interleukin-6 are resistant to high-fat diet-induced increases in body weight and b ody fat. Brain Behav Immun 2010; 24: 119-126.
71. Sadagurski M, Norquay L, Farhang J, D'Aquino K, Copps K, White MF. Human IL6 enhances leptin action in mice. Diabetologia 2010 53: 525-535.
72. Zahs A, Bird M, Ramirez L, Choudhry M, Kovacs E. Anti-IL-6 antibody treatment but not IL-6 knockout improves intestinal barrier function and reduces infla mmation after binge ethanol exposure and burn injury. Shock 2013; 39: 373-379.
73. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev 2008; 88: 1379-1406.
74. Ostrowski K, Rohde T, Zacho M, Asp S, Pedersen B. Evidence that interleukin-6 is produced in human skeletal muscle during prolonged running. J Physiol 1998; 508 (Pt 3 ), 949-953.
75. Starkie RL, Rolland J, Angus DJ, Anderson MJ, Febbraio MA. Circulating monocytes are not the source of elevations in plasma IL-6 and TNF-alpha levels after prolonged running. Am J Physiol Cell Physiol 2001; 280: C769-C774.
76. Steensberg A, van Hall G, Osada T, Sacchetti M, Saltin B, Klarlund Pedersen B. Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-ind uced increase in plasma interleukin-6. J Physiol 2000; 529 (Pt 1), 237-242.
77. Lauritzen H, Brandauer J, Schjerling P, Koh H-J, Treebak J, Hirshman M et al. Contraction and AICAR stim ulate IL-6 vesicle depletion from skeletal muscle fibers in vivo. Diabetes 2013; 62: 3081-3092.
78. Febbraio MA, Hiscock N, Sacchetti M, Fischer CP, Pedersen BK. Interleukin-6 is a novel fact or mediating glucose homeostasis during skeletal muscle contraction. Diabetes 2004; 53: 1643-1648.
79. Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, Ramm G et al. Interleu kin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 2006; 55: 2688-2697.
80. Bienso̧ R, Knudsen J, Brandt N, Pedersen P, Pilegaard H. Effects of IL-6 on pyruvate dehydrogenase regulation in mouse skeletal muscle. Pflugers Arch (e-pub ahead of print 14 November 2013; doi:10.1007/s00424-013-1399-5).
81. Al-Khalili L Bouzakri K Glund S Lonnqvist F Koistinen HA Krook A Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle Mol Endocrinol 2006 20 3364-3375.
82. O'Neill HM, Palanivel R, Wright DC, MacDonald T, Lally JS, Schertzer JD et al. IL-6 is not essential for exercise-induced increases in glucose uptake. J Appl Physiol 2013; 114: 1151-1157.
83. Benrick A, Wallenius V, Asterholm I. Interleukin-6 mediates exercise-induced increase in insulin sensitivity in mice. Exp Physiol 2012; 97: 1224-1235.
84. Ellingsgaard H, Hausel mann I, Schuler B, Habib AM, Baggio LL, Meier DT et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 2012; 17: 1481-1489.
85. Shirazi R, Palsdottir V, Collander J, Anesten F, Vogel H, Langlet F et al. Glucagon-like peptide receptor induced suppression of food intake, and body weight is mediated by central IL-1 and IL-6. Proc Natl Acad Sci USA 2013; 110: 16199-16204.
86. Watt MJ, Dzamko N, Thomas WG, Rose-John S, Ernst M, Carling D et al. CNTF reverses obesity-induced insulin resistanc e by activating skeletal muscle AMPK. Nat Med 2006; 12: 541-548.
87. de Waal Malefyt R, Abrams J, Bennett B, Figdor C, de Vries J. Interleukin 10(IL-10) inhibits cytokine synthesis by human mo nocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174: 1209-1220.
88. Kreutz M, Ackermann U, Hauschildt S, Krause SW, Riedel D, Bessler W et al. A comparative analysis of cytokine production and tolerance induction by bacterial lipopeptides, lipopolysaccharides and Staphyloccou s aureus in human monocytes. Immunology 1997; 92: 396-401.
89. Shoelson S, Lee J, Yuan M. Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity-and diet-induced insulin resistance. I nt J Obes Relat Metab Disord 2003; 27 Suppl 3: 52.
90. Whitham M, Chan MHS, Pal M, Matthews VB, Prelovsek O, Lunke S et al. Contraction-induced IL-6 gene transcription in skeletal muscle is regulated by c-jun terminal kinase/Activator protein-1. J Biol Chem 2012; 287: 10771-10779.
91. Frost RA, Nystrom GJ, Lang CH. Lipopolysaccharide and proinflammatory cytokines stimulate interleukin-6 expression in C2C12 myoblasts: role of the Jun NH2-terminal kinase. Am J Physiol Regul Integr Comp Physiol 2003; 285: R1153-R1164.
92. Sabio G, Das M, Mora A, Zhang Z, Jun JY, Ko HJ et a l. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 2008; 322: 1539-1543.
93. Goodyear L, Chang P, Sherwood D, Dufresne S, Moller D. Effects of e xercise and insulin on mitogen-activated protein kinase signaling pathways in rat skeletal muscle. Am J Physiol 1996; 271 (2 Pt 1), 8.
94. Aronson D, Boppart MD, Dufresne SD, Fielding RA, Goodyear LJ. Exercise stimulates c-Jun NH2 kinase activity and c-Jun transcriptional activity in human skeletal muscle. Biochem Biophys Res Commun 1998; 251: 106-110.
95. Weston C, Davis R. The JNK signal transduction pathway. Curr Opin Cell Biol 2007; 19: 142-149.
96. Vallerie S, Hotamisligil Gk. The role of JNK proteins in metabolism. Sci Transl Med 2010; 2: 60rv5.
97. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420: 333-336.
98. Pal M, Wunderlich CM, Spohn G, Bronneke HS, Schmidt-Supprian M, Wunderlich FT. Alteration of JNK-1 signaling in skeletal muscle fails to affect glucose homeostasis and obesity-associated insulin resistance in mice. PLoS One 2013; 8: e 54247.
99. Pillon N, Arane K, Bilan P, Chiu T, Klip A. Muscle cells challenged with saturated fatty acids mount an autonomous inflammatory response that activates macrophages. Cell Commun Signal 2012; 10: 30.
100. Kraakman M, Allen T, Whitham M, Iliades P, Kammoun H, Estevez E et al. Targeting gp130 to prevent inflammation and promote insulin action. Diabetes Obes Metab 2013; 15 Suppl 3: 170-175.
101. Krebs DL Hilton DJ SOCS proteins: negative regulators of cytokine signaling Stem Cells 2001 19 378-387.
102. Adser H, Wojtaszewski JF, Jakobsen AH, Kiilerich K, Hidalgo J, Pilegaard H. Interleukin-6 modifies mRNA expression in mouse skeletal muscle. Acta Physiol (Oxf) 2011; 202: 165-173.
103. Harder-Lauridsen NW, Krogh-Madsen R, Holsty J, Plomgaard P, Leick L, Pedersen BKP et al. The effect of IL-6 on the insulin sensitivity in patients with type 2 diabetes. Am J Physiol Endocrinol Metab (e-pu b ahead of print 28 January 2014; doi:10.1152/ajpendo.00571.2013).
104. Wan Z, Perry CG, Macdonald T, Chan CB, Holloway GP, Wright DC. IL-6 is not necessary for the regulation of adipose mitochondrial content. Plos ONE 7: e51233.